Novartis Launches Phase III Study of Hydroxychloroquine in COVID-19 Patients

Novartis plans to begin study enrolment of the 440 patient trial in US over next few weeks. Patients will be randomised to hydroxychloroquine as monotherapy or combination with azithromycin or placebo, in addition to standard of care for covid-19.


Biospace Inc.